SG11201900868XA - Ido1 inhibitor and preparation method and application thereof - Google Patents
Ido1 inhibitor and preparation method and application thereofInfo
- Publication number
- SG11201900868XA SG11201900868XA SG11201900868XA SG11201900868XA SG11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA SG 11201900868X A SG11201900868X A SG 11201900868XA
- Authority
- SG
- Singapore
- Prior art keywords
- application
- preparation
- ido1 inhibitor
- ido1
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610631523 | 2016-08-02 | ||
| CN201610797622 | 2016-08-30 | ||
| PCT/CN2017/095571 WO2018024208A1 (zh) | 2016-08-02 | 2017-08-02 | Ido1抑制剂及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900868XA true SG11201900868XA (en) | 2019-02-27 |
Family
ID=61073210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900868XA SG11201900868XA (en) | 2016-08-02 | 2017-08-02 | Ido1 inhibitor and preparation method and application thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20190169140A1 (zh) |
| EP (1) | EP3495354A4 (zh) |
| JP (1) | JP2019527699A (zh) |
| KR (1) | KR20190034318A (zh) |
| CN (1) | CN109563060B (zh) |
| AU (1) | AU2017306487A1 (zh) |
| BR (1) | BR112019001980A2 (zh) |
| CA (1) | CA3032544A1 (zh) |
| RU (1) | RU2019104899A (zh) |
| SG (1) | SG11201900868XA (zh) |
| WO (1) | WO2018024208A1 (zh) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3389783A4 (en) | 2015-12-15 | 2019-05-15 | Merck Sharp & Dohme Corp. | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| CN107033097B (zh) * | 2016-02-04 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
| UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
| WO2018214958A1 (zh) * | 2017-05-25 | 2018-11-29 | 山东绿叶制药有限公司 | Ido1抑制剂的晶型及其制备方法 |
| CN109942565B (zh) * | 2017-12-20 | 2021-03-26 | 海创药业股份有限公司 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法和用途 |
| WO2019149159A1 (zh) * | 2018-02-02 | 2019-08-08 | 山东绿叶制药有限公司 | 一种包含噁二唑类衍生物的组合物及其制备方法和应用 |
| CN110143955B (zh) * | 2018-02-11 | 2023-01-20 | 中国科学院上海药物研究所 | 含杂环侧链的噁二唑衍生物、合成方法及其应用 |
| CN110343098B (zh) * | 2018-04-04 | 2023-05-26 | 中国科学院上海药物研究所 | 一类噁二唑类化合物及其制备方法、药物组合物和用途 |
| CN110407765B (zh) * | 2018-04-28 | 2022-12-06 | 上海挚盟医药科技有限公司 | 1,2,5-噁二唑类衍生物、其制备方法及其在医药上的应用 |
| CN109438513B (zh) * | 2018-10-25 | 2020-05-12 | 中国药科大学 | 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 |
| CN112315954A (zh) * | 2020-11-24 | 2021-02-05 | 烟台大学 | 紫杉醇和ido1小分子抑制剂复方药物组合物及其用途 |
| CN114409610B (zh) * | 2022-03-29 | 2022-06-10 | 山东大学 | 噁二唑衍生物及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1879573T1 (sl) * | 2005-05-10 | 2013-04-30 | Incyte Corporation Experimental Station | Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te |
| ES2540561T3 (es) * | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| NO2824100T3 (zh) * | 2008-07-08 | 2018-07-21 | ||
| US10034939B2 (en) * | 2012-10-26 | 2018-07-31 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
| CN105481789B (zh) * | 2014-09-15 | 2020-05-19 | 中国科学院上海有机化学研究所 | 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法 |
| CN106565696B (zh) * | 2015-10-09 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | 噁二唑类衍生物、其制备方法及其在医药上的应用 |
| EP3389783A4 (en) * | 2015-12-15 | 2019-05-15 | Merck Sharp & Dohme Corp. | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
| CN105646389B (zh) * | 2016-01-28 | 2019-06-28 | 中国科学院上海有机化学研究所 | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 |
| CN107954999B (zh) * | 2016-10-17 | 2023-01-24 | 上海医药集团股份有限公司 | 含噁二唑环化合物、制备方法、中间体、组合物及应用 |
| UY37466A (es) * | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
| WO2018214958A1 (zh) * | 2017-05-25 | 2018-11-29 | 山东绿叶制药有限公司 | Ido1抑制剂的晶型及其制备方法 |
| WO2018228381A1 (zh) * | 2017-06-13 | 2018-12-20 | 山东绿叶制药有限公司 | 1,2,5-恶二唑化合物制备方法及其中间体 |
| WO2019047920A1 (zh) * | 2017-09-08 | 2019-03-14 | 山东绿叶制药有限公司 | 作为ido1抑制剂的噁二唑类衍生物的晶型及其制备方法 |
| WO2019149159A1 (zh) * | 2018-02-02 | 2019-08-08 | 山东绿叶制药有限公司 | 一种包含噁二唑类衍生物的组合物及其制备方法和应用 |
-
2017
- 2017-08-02 BR BR112019001980-4A patent/BR112019001980A2/pt not_active IP Right Cessation
- 2017-08-02 CN CN201780039482.3A patent/CN109563060B/zh active Active
- 2017-08-02 AU AU2017306487A patent/AU2017306487A1/en not_active Abandoned
- 2017-08-02 SG SG11201900868XA patent/SG11201900868XA/en unknown
- 2017-08-02 KR KR1020197006245A patent/KR20190034318A/ko not_active Application Discontinuation
- 2017-08-02 RU RU2019104899A patent/RU2019104899A/ru unknown
- 2017-08-02 WO PCT/CN2017/095571 patent/WO2018024208A1/zh unknown
- 2017-08-02 EP EP17836390.9A patent/EP3495354A4/en not_active Withdrawn
- 2017-08-02 CA CA3032544A patent/CA3032544A1/en not_active Abandoned
- 2017-08-02 US US16/322,914 patent/US20190169140A1/en not_active Abandoned
- 2017-08-02 JP JP2019505484A patent/JP2019527699A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018024208A1 (zh) | 2018-02-08 |
| BR112019001980A2 (pt) | 2019-05-07 |
| RU2019104899A (ru) | 2020-08-21 |
| CN109563060A (zh) | 2019-04-02 |
| AU2017306487A1 (en) | 2019-02-21 |
| CA3032544A1 (en) | 2018-02-08 |
| US20190169140A1 (en) | 2019-06-06 |
| EP3495354A4 (en) | 2020-01-15 |
| JP2019527699A (ja) | 2019-10-03 |
| KR20190034318A (ko) | 2019-04-01 |
| EP3495354A1 (en) | 2019-06-12 |
| RU2019104899A3 (zh) | 2020-08-21 |
| CN109563060B (zh) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900868XA (en) | Ido1 inhibitor and preparation method and application thereof | |
| CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
| PH12016500024A1 (en) | Bromodomain inhibitor | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| WO2018086591A8 (zh) | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| MX2018009633A (es) | Inhibidor de indoleamina-2,3-dioxigenasa (ido). | |
| WO2017075629A3 (en) | Wee 1 kinase inhibitors and methods of making and using the same | |
| WO2016172496A8 (en) | Lsd1 inhibitors and uses thereof | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| EP4316591A3 (en) | Oxysterols and methods of use thereof | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| MY182884A (en) | Pyrazole-amide compound and medicinal uses therefor | |
| PH12017501652B1 (en) | Kv1.3 inhibitors and their medical application | |
| MX2017007607A (es) | Inhibidores de necrosis celular y metodos relacionados. | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| PH12019500875A1 (en) | Pyridone compound as c-met inhibitor | |
| ZA202200511B (en) | Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| MX2019002901A (es) | Tratamiento de esclerosis multiple con chs-131. | |
| GEP20186879B (en) | Cycloalkyl-linked diheterocycle derivatives |